Clinical trials: SLE, open to volunteers
Autoimmune Diseases, Systemic Lupus Erythematosus
A Study to Test CRT-402 in Refractory Autoimmune Disease
Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis
- Trial name
- NCT07778446
- Testing
- CRT-402
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- Myeloid Therapeutics
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Sjogren's Syndrome (SS), Inflammatory Myopathy
- Trial name
- NCT07123519
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 18 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)
- Trial name
- NCT06941129
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Systemic Lupus Erythematous (SLE)
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
This pilot clinical study aims to evaluate the effectiveness of Chimeric Antigen Receptor (CAR) T-cell therapy in treating severe, refractory systemic lupus erythematosus (SLE), an autoimmune disease driven by autoreactive…
- Trial name
- NCT06710717
- Testing
- CD19 CAR-T cells
- Where
- Malaysia
- Volunteers
- 5 people
- Sponsor
- National University of Malaysia
Systemic Lupus Erythematosus, Inflammatory Myopathy
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
- Trial name
- NCT06794008
- Testing
- BCMA-CD19 CAR-T therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Lupus Erythematosus, Systemic
Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by heterogeneous clinical manifestations ranging from mild cutaneous involvement to severe multi-organ damage.
- Trial name
- NCT06881290
- Testing
- Vunakizumab (IL-17A inhibitor)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese SLE Treatment And Research Group
Systemic Lupus Erythematous (SLE)
LUpus Eritematoso Sistemico NETwork and Registry
The LUNET Registry is intended to serve as a comprehensive primary data source, capturing real-world longitudinal clinical information, and the heterogeneity of patient presentations that are often underrepresented in traditional…
- Trial name
- LUNET (NCT07175610)
- Where
- 16 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Società Italiana di Allergologia, Asma e Immunologia Clinica
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy
- Trial name
- NCT05859997
- Testing
- BRL-301
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bioray Laboratories
Systemic Lupus Erythematosus, Systemic Scleroderma
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase.
- Conditions
- Systemic Lupus Erythematosus, Systemic Scleroderma, ANCA-associated Vasculitis, Antiphospholipid Syndrome
- Trial name
- AutoB-Tetramer (NCT07251179)
- Testing
- blood draw
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
This study is an open-label, multiple ascending dose investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CC312 in adult patients with relapsed or…
- Conditions
- SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis
- Trial name
- NCT07193810
- Testing
- CC312
- Where
- China
- Volunteers
- 6 people
- Sponsor
- CytoCares Inc
Systemic Lupus Erythematosus
A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of QLS4131 in subjects with…
- Trial name
- NCT07001839
- Testing
- QLS4131 for Injection.
- Volunteers
- 108 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lupus Erythematosus, Systemic
Sirolimus Treatment Of Patients With SLE
Phase II Double-blind, placebo-controlled, randomized treatment trial with two arms: one SIROLIMUS arm with 92 patients and one placebo arm with 92 patients.
- Trial name
- STOPSLE (NCT04736953)
- Testing
- Sirolimus
- Volunteers
- 220 people
- Sponsor
- State University of New York - Upstate Medical University
Lupus Nephritis, Autoimmune Diseases
A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease
ADI-202300103 is a phase 1 multicenter, open label, dose finding and dose expansion, safety/efficacy study in patients with autoimmune disease.
- Conditions
- Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)
- Trial name
- NCT06375993
- Testing
- ADI-001, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- Adicet Therapeutics
System Lupus Erythematosus(SLE)
Clinical Utility of Serum Ribonuclease 1(RNASE1) as a Biomarker of Lupus Nephritis.
This study will identify the level of serum Riboneuclease 1 in systemic lupus patients and compare between its level in lupus nephritis and non nephritis.
- Trial name
- NCT07763821
- Volunteers
- 128 people
- Sponsor
- Assiut University
Systemic Lupus Erthematosus (SLE)
KN5501 Cell Injection for Refractory SLE(CLEAR)
The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE).
- Trial name
- CLEAR (NCT07358988)
- Testing
- KN5501 cell injection
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Ruitherapeutics Co., LTD
Systemic Lupus Erythematosus (SLE)
An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
- Trial name
- NCT06945068
- Testing
- GB261
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus (Sle)
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness.
- Trial name
- NCT06032923
- Testing
- Nicotinamide Riboside
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lupus Erythematosus, Systemic
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus…
- Trial name
- NCT06897930
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Systemic Lupus Erythematosus
Transcutaneous Vagus Nerve Stimulation in SLE
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease. Joint and muscle pain and fatigue are extremely common among patients and contribute to a reduced quality of life.
- Trial name
- TvSSLE (NCT06987565)
- Testing
- Active vagus nerve stimulation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwell Health
Systemic Lupus Erythematosus
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)
- Trial name
- NCT06791772
- Testing
- CM313 injection
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Keymed Biosciences Co.Ltd